Pharmacists Report First Clinical Protocol for Managing Acute 7-OH Withdrawal Using Buprenorphine

Why it matters

As concentrated 7-hydroxymitragynine products proliferate at gas stations and smoke shops, pharmacists and clinicians need evidence-based protocols for managing withdrawal — this case report offers the first structured clinical approach.

The big picture

Kratom and its concentrated derivative 7-OH have grown increasingly available in retail settings, raising addiction medicine concerns. While buprenorphine is a well-established opioid use disorder treatment, its application to 7-OH-specific withdrawal had not been formally documented until this case report.

Key findings

• A 43-year-old male with opioid use disorder presented after abruptly stopping 360 mg/day of concentrated 7-OH, his last dose roughly 48 hours prior
• Symptoms included nausea, diarrhea, abdominal cramping, restlessness, chills, and anxiety — consistent with moderate opioid withdrawal (COWS score: 5)
• The patient had escalated from standard kratom to concentrated 7-OH 18 months earlier, reporting faster and stronger opioid-like effects with smaller quantities
• Emergency management included buprenorphine/naloxone 4/1 mg sublingual plus adjunct medications (clonidine, ondansetron, loperamide, methocarbamol, NSAIDs, acetaminophen)
• A Naranjo causality assessment yielded a score of 6, supporting 7-OH as the probable cause of withdrawal

What they say

The authors note: "Concentrated 7-OH products differ from kratom leaf and can produce dependence and withdrawal; pharmacists should screen for these products, time buprenorphine initiation to moderate withdrawal, provide harm-reduction counseling, and incorporate evolving state regulations into patient education."

Bottom line

Concentrated 7-OH products are potent enough to cause opioid-level physical dependence and classic withdrawal — and buprenorphine can manage the acute crisis, but clinicians must screen for these products proactively.